Trial Profile
Evaluation of Effectiveness of GSK Biologicals' Pneumococcal Conjugate Vaccine 1024850A Against Invasive Disease.
Status:
Completed
Phase of Trial:
Phase III/IV
Latest Information Update: 07 Sep 2023
Price :
$35
*
At a glance
- Drugs Pneumococcal 10-valent vaccine conjugate (Primary) ; Hepatitis A vaccine inactivated; Hepatitis B vaccine recombinant
- Indications Diphtheria; Haemophilus infections; Hepatitis A; Hepatitis B; Nosocomial pneumonia; Pneumococcal infections; Pneumonia; Tetanus
- Focus Registrational; Therapeutic Use
- Acronyms FinIP
- Sponsors GlaxoSmithKline; GSK
- 20 May 2019 Results published in the Vaccine
- 01 Mar 2018 Results assessing vaccine preventable disease incidence using patient data from NCT00861380 and NCT00839254 trials published in the Vaccine
- 12 Jul 2017 Results assessing Direct and Indirect Effectiveness of the Ten-Valent Pneumococcal Conjugate Vaccine Against Carriage in three FinIP trials (FinIP, FinIPcarr and FinIP-carriage) published in the Pediatric Infectious Disease Journal